Want to see NMRA full AI Analyst Report?
NMRA Stock Chart & Stats
$1.49
$0.18(12.08%)
At close: 4:00 PM EDT
$1.49
$0.18(12.08%)
Day’s Range― - ―
52-Week Range$0.83 - $3.65
Previous CloseN/A
Volume485.06K
Average Volume (3M)490.26K
Market Cap
$306.27M
Enterprise Value$251.20
Total Cash (Recent Filing)$116.83M
Total Debt (Recent Filing)$340.00K
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Nov 04, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding187,895,900
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside252.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageMinimal borrowing reduces interest and refinancing risk while the company funds high-cost development programs. Although the balance sheet has weakened, very low debt preserves flexibility to allocate capital toward clinical priorities.
Cost Discipline And RunwayLower clinical and personnel costs, combined with projected funding into Q3 2027, give Neumora time to generate clinical milestones without immediate financing pressure. This supports a more focused development strategy after restructuring.
NMRA-215 Development ProgressImproved toxicology results remove a key obstacle to NMRA-215 entering human testing. Its reported efficacy, semaglutide combination potential and cardiometabolic biomarker effects could broaden the pipeline beyond neuroscience if clinical results validate the thesis.
Bears Say
Pre-Revenue Business ModelNeumora lacks marketed products and recurring commercial revenue, so value depends on clinical success, partnerships or future financing. Persistent losses leave no operating income base to absorb setbacks or independently fund the pipeline.
Heavy Cash Burn And Funding RiskSustained negative cash generation consumes the company’s financial cushion and makes continued external funding important. Declining equity and assets increase the risk of dilution or strategic constraints as additional clinical spending is required.
Late-Stage Pipeline SetbackRemoving a failed Phase 3 asset eliminates a nearer-term path to commercialization and increases reliance on earlier programs such as NMRA-511, NMRA-898 and NMRA-215. This raises execution and pipeline concentration risk.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.83 and its highest was $3.65 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $306.27M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 73 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.01.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.2.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 187,895,900 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -7.514%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.25 (252.35% Upside)
$5.25 (252.35% Upside)
Blogger Sentiment
Bullish
NMRA Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 5.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $699.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.04%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
NMRA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong scientific and clinical momentum across several programs with multiple near-term catalysts (NMRA-511, navacaprant KOASTAL-2/3, NMRA-898) and compelling preclinical/early clinical data (notably NMRA-511 effect sizes and NMRA-215 DIO results). However, a non-dose-dependent adverse signal in a 13-week rat tox study for NMRA-215, associated study conduct issues and the need to repeat toxicology introduce timeline, regulatory and cost risk for that program. Financial runway of $182.5M into Q3 2027 is adequate for the near term but will require careful capital allocation as multiple programs advance. Overall, positives on pipeline progress and enrollments outweigh the headwinds from the NMRA-215 tox delay and finite cash runway, but risks remain tied to upcoming pivotal readouts.View all NMRA earnings summariesNMRA Stock 12 Month Forecast
Average Price Target
$5.25
▲(252.35% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
58.41% Insiders
3.21% Mutual Funds
20.57% Other Institutional Investors
11.60% Public Companies and
Individual Investors